Follow-up of drug treatment for people with Graves' disease in China

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective follow-up of adults with newly diagnosed or relapsed Graves' disease treated with antithyroid drugs at a tertiary hospital in China. The study records remission and relapse rates, compares outcomes and adverse reactions between high- and low-dose methimazole, and seeks risk factors for relapse. It will also analyze TRAb test sensitivity and specificity for diagnosis and its role in predicting recurrence, and monitor liver enzymes and blood counts during treatment. The investigators plan to use the collected data to develop relapse-risk prediction software.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥18 years old.
2. Newly diagnosed GD and GD relapses.

Exclusion Criteria:

1. Patients with active infiltrative exophthalmos in GD were excluded.
2. Patients with other autoimmune diseases affecting thyroid function were excluded.
3. Excluding patients with combined malignancies and other serious diseases.

Where it's running

• The First Affiliated Hospital of China Medical University
  Shenyang, Liaoning, China Recruiting

Study contacts

• Study coordinator: Xiaochun Teng, Medical Doctor (MD)
• Email: tengxiaochun@126.com
• Phone: +8613704049020

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Efgartigimod for Graves' Disease in adults

  We are testing if efgartigimod given under the skin can help adults with Graves' disease by improving thyroid function and whether it is safe and tolerable.

  Recruiting at 35 sites Phase 3 argenx · Carlsbad, California and 34 other locations · NCT07570316

• ETHY-001 safety and activity in Thyroid Eye Disease (TED)

  This study tests ETHY-001 versus placebo to see if it is safe, tolerable, and shows activity in people with thyroid eye disease.

  Recruiting at 2 sites Phase 1 Ethyreal Bio, Inc. · Orland Park, Illinois and 2 other locations · NCT07885605

• Early risk stratification of thyroid eye disease in newly diagnosed Graves' disease

  This study tests whether early eye-related signs, blood and tear biomarkers, or eye surface features can predict who with Graves’ disease will develop thyroid eye disease within a year.

  Recruiting University of Copenhagen · Herlev · NCT07812194

• Felzartamab for Graves’ Disease: See if it helps control thyroids and reduce need for ATDs

  This study tests felzartamab vs placebo in adults with Graves’ disease to see if it can normalize thyroid hormones and let people stop anti-thyroid drugs.

  Recruiting at 14 sites Phase 2 Biogen · Glendale, Arizona and 13 other locations · NCT07722546

• AI-based MRI and ultrasound for thyroid-related eye disease

  This study tests an AI model using orbital MRI and eye ultrasound to help diagnose activity and severity of thyroid-associated ophthalmopathy and predict its course in adults.

  Recruiting Shanghai Changzheng Hospital · Shanghai, Huangpu District · NCT07716397

• YB-101 for Graves' Disease: safety, dosing, and how it works

  This study tests YB-101 versus placebo in adults with Graves' disease to see if it is safe, tolerated, and whether it can help thyroid symptoms over about 40 weeks.

  Recruiting at 25 sites Phase 2 Yarrow Bioscience, Inc. · Gilbert, Arizona and 31 other locations · NCT07682896

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.